These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
183 related articles for article (PubMed ID: 29589987)
61. Update on systemic therapy of advanced non-small-cell lung cancer. Cufer T; Knez L Expert Rev Anticancer Ther; 2014 Oct; 14(10):1189-203. PubMed ID: 25098682 [TBL] [Abstract][Full Text] [Related]
62. Use of tyrosine kinase inhibitors for chronic myeloid leukemia: management of patients and practical applications for pharmacy practitioners. Wong SF; Mirshahidi H Ann Pharmacother; 2011 Jun; 45(6):787-97. PubMed ID: 21672900 [TBL] [Abstract][Full Text] [Related]
63. ITK inhibition for the targeted treatment of CTCL. Bustos-Villalobos I; Bergstrom JW; Haigh NE; Luna JI; Mitra A; Marusina AI; Merleev AA; Wang EA; Sukhov A; Sultani H; Liu R; Bhardwaj G; Guo W; Kung HJ; Lam KS; Maverakis E J Dermatol Sci; 2017 Jul; 87(1):88-91. PubMed ID: 28434812 [No Abstract] [Full Text] [Related]
64. Anaplastic lymphoma kinase (ALK) inhibitors in the treatment of ALK-driven lung cancers. Roskoski R Pharmacol Res; 2017 Mar; 117():343-356. PubMed ID: 28077299 [TBL] [Abstract][Full Text] [Related]
65. Drug combination approach to overcome resistance to EGFR tyrosine kinase inhibitors in lung cancer. Tong CWS; Wu WKK; Loong HHF; Cho WCS; To KKW Cancer Lett; 2017 Oct; 405():100-110. PubMed ID: 28774798 [TBL] [Abstract][Full Text] [Related]
66. The association between clinical prognostic factors and epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) efficacy in advanced non-small-cell lung cancer patients: a retrospective assessment of 94 cases with EGFR mutations. Lin JH; Lin D; Xu L; Wang Q; Hu HH; Xu HP; He ZY Oncotarget; 2017 Jan; 8(2):3412-3421. PubMed ID: 27926500 [TBL] [Abstract][Full Text] [Related]
67. Tyrosine kinase inhibitors for epidermal growth factor receptor gene mutation-positive non-small cell lung cancers: an update for recent advances in therapeutics. Chung C J Oncol Pharm Pract; 2016 Jun; 22(3):461-76. PubMed ID: 25855240 [TBL] [Abstract][Full Text] [Related]
68. Application of the American society of clinical oncology frameworks to compare tyrosine kinase inhibitors used in first line treatment of metastatic renal cell carcinoma: had we solved the mystery? Ahmed SH; Elbaghdady N; Alorabi M Expert Rev Anticancer Ther; 2017 Nov; 17(11):1061-1070. PubMed ID: 28862039 [TBL] [Abstract][Full Text] [Related]
69. New development of inhibitors targeting the PI3K/AKT/mTOR pathway in personalized treatment of non-small-cell lung cancer. Sun Z; Wang Z; Liu X; Wang D Anticancer Drugs; 2015 Jan; 26(1):1-14. PubMed ID: 25304988 [TBL] [Abstract][Full Text] [Related]
73. Molecular Testing Guideline for the Selection of Patients With Lung Cancer for Targeted Therapy. Copur MS; Crockett D; Gauchan D; Ramaekers R; Mleczko K J Clin Oncol; 2018 Jul; 36(19):2006. PubMed ID: 29763342 [No Abstract] [Full Text] [Related]
74. The need for an individual approach to lung cancer treatment. Shigematsu H; Toyooka S; Suzuki M PLoS Med; 2006 Apr; 3(4):e206. PubMed ID: 16626260 [No Abstract] [Full Text] [Related]
75. [Research progresses in targeted therapies for gastric cancer]. Pan SY; Fang JY Zhonghua Nei Ke Za Zhi; 2020 Feb; 59(2):148-152. PubMed ID: 32074690 [TBL] [Abstract][Full Text] [Related]
76. Harnessing the Breakthroughs in Lung Cancer Treatment. Oncology (Williston Park); 2020 Dec; 34(12):536-538. PubMed ID: 33395493 [TBL] [Abstract][Full Text] [Related]